RxDoctor Payments DataLook up a doctor →

Mark Ling

Procedural Dermatology · Newnan, GANPI 1639153638

Payments from drug & device makers

$898,336in general payments, 2019–2025

Across 153 payments — averaging $5871.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$296K
  • Aclaris Therapeutics, Inc.$182K
  • Bausch Health US, LLC$83K
  • Bristol Myers Squibb$80K
  • Pfizer$63K
  • Sanofi US Services Inc.$59K
  • plus $135K from 15 others
$161,357in research payments, 2019–2025

Across 103 payments — averaging $1566.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Ichnos Glenmark Innovation Inc$77K
  • Glenmark Pharmaceuticals Inc., USA$57K
  • Eli Lilly$27K

What the payments were for

  • Food & beverage$60682%
  • Education$13118%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few procedural dermatology providers in Georgiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$239,856
Medicare patients
965
Services billed
4,156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa28$578,296
Humira(Cf) PenAdalimumab54$346,269
Enbrel SureclickEtanercept36$263,834
TremfyaGuselkumab13$176,891
Cosentyx Sensoready (2 Pens)Secukinumab15$107,381
Humira(Cf)Adalimumab13$88,550
Dupixent SyringeDupilumab15$58,080
OpzeluraRuxolitinib Phosphate16$32,558
Acitretin25$16,363
Ketoconazole205$3,500
Ivermectin13$3,296
Calcipotriene18$2,067
Metronidazole25$1,977
Tacrolimus21$1,843
Clobetasol Propionate24$1,160

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira(Cf)$121$88,55013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few procedural dermatology providers in Georgiaon file to place this against a meaningful peer group, so we don't.

Other procedural dermatology in Newnan

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →